What is Optimi?
Optimi Health Corp. operates as a specialized Canadian pharmaceutical manufacturer, distinguished by its Health Canada licensure to produce and export MDMA and botanical psilocybin. With two 10,000 square-foot facilities in Princeton, British Columbia, the firm maintains a robust Drug Establishment Licence, enabling it to serve as a critical supply chain partner for Australia's Authorised Prescribers Scheme. By focusing on treatment-resistant depression and PTSD, Optimi bridges the gap between clinical research and commercial-grade production, supporting trials across Canada and Israel while preparing for potential U.S. market entry.
How much funding has Optimi raised?
Optimi has raised a total of $3.3M across 2 funding rounds:
Debt
$2.2M
Share Placement
$1.1M
Debt (2023): $2.2M, investors not publicly disclosed
Share Placement (2024): $1.1M, investors not publicly disclosed
Key Investors in Optimi
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Optimi?
With this major strategic investment, Optimi is well-positioned to accelerate its clinical trial support and enhance its manufacturing throughput. The company's roadmap emphasizes the optimization of its supply chain to meet the rigorous demands of global regulatory bodies. As the firm navigates the complexities of DEA rescheduling and international export protocols, the current financing serves as a foundational pillar for scaling its proprietary psychedelic formulations. Future growth will likely center on deepening its footprint in the North American market and expanding its portfolio of therapeutic applications for mental health disorders.
See full Optimi company page
